SCHEMBL4520609

SCHEMBL4520609

C[C@@H](COc1ccccc1C(N)=O)NS(=O)(=O)c1ccc(-c2cc(C(F)(F)F)n(C)n2)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
PTGES2 Q9H7Z7 1/20 0.51
POLB P06746 1/20 0.44
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.35
HPGD P15428 1/20 0.35
MAPK8 P45983 1/20 0.34
MAPK10 P53779 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
ADRA1D P25100 2/20 0.34
ADRA1A P35348 2/20 0.34
ADRA1B P35368 2/20 0.34
NEK2 P51955 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
PARP1 P09874 1/20 0.33
ADRB2 P07550 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4559868 0.91 GAA (0.43) GAAL3MBTL1PTGES2POLBTP53
Ethane SCHEMBL4559870 0.83 HTT (0.35) GAAL3MBTL1PTGES2TP53MAPT
SCHEMBL4513347 0.82 NR3C1 (0.55) GAAL3MBTL1PTGES2POLBALDH1A1
SCHEMBL4516667 0.80 NR3C1 (0.56) GAAL3MBTL1PTGES2POLBALDH1A1
SCHEMBL4782481 0.73 NR3C1 (0.61) GAAL3MBTL1PTGES2
SCHEMBL4512981 0.70 NR3C1 (0.61) L3MBTL1HTT
SCHEMBL4517755 0.70 NR3C1 (0.61) L3MBTL1HTT
SCHEMBL4519749 0.70 NR3C1 (0.47) L3MBTL1MAPTHTTPARP1ADRA2A
SCHEMBL4517020 0.70 HTT (0.44) GAAL3MBTL1ALDH1A1MAPTHTT
SCHEMBL3474660 0.69 PTGES2 (0.58) GAAL3MBTL1PTGES2POLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 GAA 3779/4885L3MBTL1 4844/4885PTGES2 133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.